Hemay808 is a dual inhibitor targeting IgE and PDE4.
1Trial Title:A multicenter, randomized, blinded, vehicle-controlled Phase II clinical study to evaluate the safety and efficacy of different concentration dosing regimens of Hemay808 in patients with mild-to-moderate atopic dermatitis.
Target Population： Patients with mild-to-moderate atopic dermatitis
Clinical Project Description： Not currently recruiting. A previous multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial was completed to evaluate the efficacy and safety of Hemay808 in treating mild-to-moderate atopic dermatitis (AD), and to observe the in vivo exposure of Hemay808 in AD patients.
